Hepatokines and Non-Alcoholic Fatty Liver Disease: Linking Liver Pathophysiology to Metabolism

被引:28
|
作者
Kim, Tae Hyun [1 ]
Hong, Dong-Gyun [2 ,3 ]
Yang, Yoon Mee [2 ,3 ]
机构
[1] Sookmyung Womens Univ, Pharmaceut Sci Res Inst, Coll Pharm, Seoul 04310, South Korea
[2] Kangwon Natl Univ, Dept Pharm, Chunchon 24341, South Korea
[3] Kangwon Natl Univ, KNU Researcher Training Program Dev Antiviral Inn, Chunchon 24341, South Korea
基金
新加坡国家研究基金会;
关键词
ANGPTL; energy metabolism; Fetuin; FGF21; inter-organ communication; ANGIOPOIETIN-LIKE; 4; HEPATIC INSULIN-RESISTANCE; BETA-CELL PROLIFERATION; GROWTH-FACTOR; FETUIN-A; SELENOPROTEIN-P; BINDING-PROTEIN; WEIGHT-LOSS; SERUM RETINOL-BINDING-PROTEIN-4; GLUCOSE-PRODUCTION;
D O I
10.3390/biomedicines9121903
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The liver plays a key role in maintaining energy homeostasis by sensing and responding to changes in nutrient status under various metabolic conditions. Recently highlighted as a major endocrine organ, the contribution of the liver to systemic glucose and lipid metabolism is primarily attributed to signaling crosstalk between multiple organs via hepatic hormones, cytokines, and hepatokines. Hepatokines are hormone-like proteins secreted by hepatocytes, and a number of these have been associated with extra-hepatic metabolic regulation. Mounting evidence has revealed that the secretory profiles of hepatokines are significantly altered in non-alcoholic fatty liver disease (NAFLD), the most common hepatic manifestation, which frequently precedes other metabolic disorders, including insulin resistance and type 2 diabetes. Therefore, deciphering the mechanism of hepatokine-mediated inter-organ communication is essential for understanding the complex metabolic network between tissues, as well as for the identification of novel diagnostic and/or therapeutic targets in metabolic disease. In this review, we describe the hepatokine-driven inter-organ crosstalk in the context of liver pathophysiology, with a particular focus on NAFLD progression. Moreover, we summarize key hepatokines and their molecular mechanisms of metabolic control in non-hepatic tissues, discussing their potential as novel biomarkers and therapeutic targets in the treatment of metabolic diseases.
引用
收藏
页数:26
相关论文
共 50 条
  • [41] Hydrogen sulphide in liver glucose/lipid metabolism and non-alcoholic fatty liver disease
    Mateus, Ines
    Prip-Buus, Carina
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2022, 52 (03)
  • [42] Alterations of Central Liver Metabolism of Pediatric Patients with Non-Alcoholic Fatty Liver Disease
    Berndt, Nikolaus
    Hudert, Christian A.
    Eckstein, Johannes
    Loddenkemper, Christoph
    Henning, Stephan
    Bufler, Philip
    Meierhofer, David
    Sack, Ingolf
    Wiegand, Susanna
    Wallach, Iwona
    Holzhutter, Hermann-Georg
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (19)
  • [43] Non-alcoholic fatty liver disease: Epidemiology, pathophysiology and an update on the therapeutic approaches
    Abdel-Rahman, Rehab F.
    ASIAN PACIFIC JOURNAL OF TROPICAL BIOMEDICINE, 2022, 12 (03) : 99 - 114
  • [44] The role of platelets in non-alcoholic fatty liver disease: From pathophysiology to therapeutics
    Malladi, Navya
    Alam, Md Jahangir
    Maulik, Subir K.
    Banerjee, Sanjay K.
    PROSTAGLANDINS & OTHER LIPID MEDIATORS, 2023, 169
  • [45] The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease
    Perakakis, Nikolaos
    Stefanakis, Konstantinos
    Mantzoros, Christos S.
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2020, 111
  • [46] Non-alcoholic fatty liver disease in type 1 diabetes: Prevalence and pathophysiology
    Memaj, Plator
    Jornayvaz, Francois R.
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [47] Non-alcoholic fatty liver disease: Epidemiology, pathophysiology and an update on the therapeutic approaches
    Rehab F.Abdel-Rahman
    Asian Pacific Journal of Tropical Biomedicine, 2022, (03) : 99 - 114
  • [48] Precision Medicine in Fatty Liver Disease/Non-Alcoholic Fatty Liver Disease
    Valenzuela-Vallejo, Laura
    Sanoudou, Despina
    Mantzoros, Christos S.
    JOURNAL OF PERSONALIZED MEDICINE, 2023, 13 (05):
  • [49] Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
    Eslami, Layli
    Merat, Shahin
    Malekzadeh, Reza
    Nasseri-Moghaddam, Siavosh
    Aramin, Hermineh
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (12):
  • [50] Circadian Clock Genes in the Metabolism of Non-alcoholic Fatty Liver Disease
    Shi, Dongmei
    Chen, Jie
    Wang, Jiaofeng
    Yao, Jianfeng
    Huang, Yiqin
    Zhang, Gansheng
    Bao, Zhijun
    FRONTIERS IN PHYSIOLOGY, 2019, 10